[Skip to Content]
[Skip to Content Landing]
Views 138
Citations 0
Comment & Response
May 2017

Cetuximab and Radiotherapy in Laryngeal Preservanion—Reply

Author Affiliations
  • 1Department of Radiation Oncology, Hazelrig-Salter Radiation Oncology Center, University of Alabama at Birmingham, Birmingham
  • 2Eli Lilly and Company, Indianapolis, Indiana
JAMA Otolaryngol Head Neck Surg. 2017;143(5):526. doi:10.1001/jamaoto.2016.3809

In Reply We thank Drs D’Ascanio, Ricci, and Piazza for their interest in the article “Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial.”1 The contribution of the article was a retrospective subgroup analysis of a randomized trial of primary radiation with and without cetuximab for patients with locoregionally advanced head and neck cancers. Patients with advanced laryngeal and hypopharyngeal tumors often require laryngectomy if they are to undergo surgery. We examined patients with advanced laryngeal and hypopharyngeal tumors from our overall trial2,3 of patients with locoregionally advanced head and neck cancer.

×